Navigation Links
Dr. Warren Jackman Joins CryoCor Scientific Advisory Board

SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today Warren Jackman, M.D., joined the Company's Scientific Advisory Board.

"We are extremely excited to welcome Dr. Jackman to our Scientific Advisory Board," said Dr. Ed Brennan, Chief Executive Officer of CryoCor. "Dr. Jackman is a key thought leader in the field of cardiac arrhythmias and one of the most prominent electrophysiologists in the country for the treatment of atrial fibrillation. He has expressed an interest in evaluating our Cryoablation System for the treatment of AF, either as a stand-alone procedure, or in a combination procedure also using RF energy, to capitalize on the potential strengths of both energy sources. We are pleased to have another strong addition to our Scientific Advisory Board."

"My colleague, Dr. Hiroshi Nakagawa, and I have conducted several animal studies with CryoCor's Cryoablation System and are intrigued by the power, lesion size and potential safety from CryoCor's cryoablation system," said Dr. Warren Jackman. "I look forward to advising CryoCor as it evaluates its opportunity in the field of atrial fibrillation ablation."

Dr. Jackman has held active roles nationally in the Heart Rhythm Society (formerly the North American Society of Pacing and Electrophysiology) and served as director of a course on Advanced Catheter Ablation of Cardiac Arrhythmias at the American College of Cardiology. Dr. Jackman has also been an Investigator and Co-Investigator in grants from the American Heart Association, National Institutes of Health: National Heart Lung and Blood Institute, Oklahoma Health Research Program and the Whitaker Foundation.

Dr. Jackman obtained his medical degree from the University of Florida and completed his residency in Internal medicine at Bowman Gray School of Medicine, Wake Forest University. He served a Fellowship in cardiology and cardiac electrophysiology at Indiana University School of Medicine.

CryoCor's Scientific Advisory Board consists of leading physicians and researchers in the field of cardiology and cardiac electrophysiology and is active in assisting the Company's development of its products and clinical trials.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at

Forward-Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the potential advantages of CryoCor's cryoablation system and CryoCor's opportunities in the field of atrial fibrillation ablation, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's technology and the diagnosis and treatment of atrial arrhythmias; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; risks associated with the Company's ability to maintain and achieve milestones under collaborative agreements and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.

CryoCor, Inc.

Gregory J. Tibbitts

Chief Financial Officer

(858) 909-2200

The Ruth Group

Nick Laudico / Zack Kubow (investors)

(646) 536-7030 / 7020

Jason Rando (media)

(646) 536-7025

SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Global Summit on AIDS & The Church Calls for Public, Private and Parish Sectors To Unite in Response to Worldwide Pandemic: Pastor Rick and Kay Warren Host More Than 1,700 at Event Featuring International Dignitaries, Political Figures and International E
2. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
3. Friends of Warren Zevon To Play at Maverick Saloon - Raising Awareness of Asbestos Cancer, Mesothelioma
4. Governor Rendell Launches Tour to Insure in Warren County; Urges Passage of Plan to Give Access to Affordable Health Insurance
5. PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors
6. Irwin Studen Joins GetWellNetwork as Senior Vice President and Chief Financial Officer
7. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
8. John Josef Molenda Joins Firms Intellectual Property Practice as Of Counsel
9. Noted Litigator Peter Diedrich Joins Musick Peeler & Garrett LLP
10. United States Joins False Claims Act Cases Against Three New Jersey Hospitals
11. Global Sales Veteran Jack McGovern Joins MediKeeper
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: